The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Outcome of Differentiated Thyroid Cancer with Detectable Serum Tg and Negative Diagnostic 131I Whole Body Scan: Comparison of Patients Treated with High 131I Activities Versus Untreated Patients
Open accessAbstract
Detectable serum Tg levels associated with negative diagnostic (131)I whole body scan are not infrequently found in patients with differentiated thyroid cancer. Several researchers have shown that in these patients the administration of high (131)I activity (100 mCi or more) increases the sensitivity of a posttherapy diagnostic (131)I whole body scan performed a few days later and allows the detection of neoplastic foci not seen with diagnostic doses of (131)I. Empirical radioiodine treatment has also been advocated by some researchers, but its therapeutic effect is controversial. In our institute, positive serum Tg/negative diagnostic (131)I whole body scan patients were not treated with high (131)I activities before 1984; afterward, almost all patients with positive serum Tg/negative diagnostic (131)I whole body scan patients were treated with radioiodine, and a posttherapy diagnostic (131)I whole body scan was performed. In the present retrospective study we compared the outcome of these two groups of patients, 42 treated and 28 untreated, followed for mean periods of 6.7 +/- 3.8 and 11.9 +/- 4.4 yr, respectively. In the treated group the first posttherapy diagnostic (131)I whole body scan was negative in 12 patients and positive in 30 patients. (131)I treatment was further administered only in the latter group. At the end of follow-up in treated patients a complete remission (normalization of serum Tg off L-thyroxine and negative diagnostic (131)I whole body scan) was observed in 10 patients (33.3%). In 9 cases (30%) posttherapy diagnostic (131)I whole body scan became negative, and serum Tg was reduced but still detectable; in 11 patients (36.6%) serum Tg was detectable, and posttherapy diagnostic (131)I whole body scan was positive. The resolution of (131)I uptake in lung metastases was observed in 8 of 9 cases (88.8%) and in cervical node metastases in 11 of 18 cases (61.1%). In patients treated only once because the posttherapy diagnostic (131)I whole body scan was negative (n = 12), 2 patients (16.7%) were in apparent remission, 7 (58.3%) had detectable Tg values without evidence of disease, 2 (16.7%) showed lymph node metastases in the mediastinum, and 1 patient (8.3%) died because of lung metastases. Of the 28 untreated patients, none with radiological evidence of disease, serum Tg off L-thyroxine therapy became undetectable in 19 cases (67.9%), significantly reduced in 6 cases (21.4%), and unchanged or increased in 3 patients (10.7%), 1 of whom developed lung metastases 14 yr after the diagnosis. In summary, our results indicate that in patients with detectable serum Tg and negative diagnostic (131)I whole body scan, treatment with high doses of (131)I may have therapeutic utility in patients with lung metastases and, to a lesser extent, in those with lymph node metastases. However, in view of the frequent normalization of Tg values in untreated patients, we believe that treatment with (131)I should be considered according to the result of the first posttherapy scan. If positive in the lung, (131)I treatment should be continued up to total remission; surgical treatment should be preferred in patients with node metastases, and no treatment should be used in those with thyroid bed uptake or no uptake.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
TNM Classification of Malignant Tumours
(1987) · Springer eBooks · doi:10.1007/978-3-642-82982-6 · Cited by 16,049
Pineda, J. D. (1995) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.80.5.1488 · Cited by 362
Cailleux, A. F. (2000) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.85.1.175 · Cited by 357
Pacini, F., Lippi, F., Formica, N., et al. (1987) · PubMed · Cited by 265
Self-citation131 I Therapy for Elevated Thyroglobulin Levels
SCHLUMBERGER, M., MANCUSI, F., BAUDIN, E., & PACINI, F. (1997) · Thyroid · doi:10.1089/thy.1997.7.273 · Cited by 208
Self-citationSchlumberger, M. J., Arcangioli, O., Piekarski, J. D., Tubiana, M., & Parmentier, C. (1988) · PubMed · Cited by 200
Ashcraft, M. W., & Van Herle, A. J. (1981) · The American Journal of Medicine · doi:10.1016/0002-9343(81)90368-5 · Cited by 180
Travagli, J. P., Cailleux, A.-F., Ricard, M., Baudin, É., Caillou, B., Parmentier, C., & Schlumberger, M. J. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.83.8.5014 · Cited by 144
Management of Patients with Scan Negative, Thyroglobulin Positive Differentiated Thyroid Carcinoma
Wartofsky, L. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.83.12.5293-1 · Cited by 139
Serum thyroglobulin in thyroid carcinoma and other thyroid disorders
Pacini, F., Pinchera, A., Giani, C., Grasso, L., Doveri, F., & Baschieri, L. (1980) · Journal of Endocrinological Investigation · doi:10.1007/bf03348277 · Cited by 135
Self-citationPacini, F., Lari, R., Mazzeo, S., Grasso, L., Taddei, D., & Pinchera, A. (1985) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1985.tb01098.x · Cited by 134
Self-citationFDG PET of recurrent or metastatic 131I-negative papillary thyroid carcinoma.
Alnafisi, N., Driedger, A. A., Coates, G., Moote, D. J., & Raphael, S. J. (2000) · PubMed · Cited by 117
Schneider, A. B., Line, B. R., Goldman, J. M., & ROBBINS, J. J. (1981) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-53-6-1199 · Cited by 112
Pacini, F., Pinchera, A., Giani, C., Grasso, L., & Baschieri, L. (1980) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1980.tb01030.x · Cited by 95
Self-citationMcDougall, I. R. (1997) · Thyroid · doi:10.1089/thy.1997.7.669 · Cited by 71
Serum Thyroglobulin in the Management of Patients With Thyroid Cancer
Barsano, C. P. (1982) · Archives of Internal Medicine · doi:10.1001/archinte.1982.00340170119020 · Cited by 51
Wartofsky, L., Sherman, S. I., Gopal, J., et al. (1998) · Cited by 49
Cited by
Haugen, B. R., Alexander, E. K., Bible, K. C., Doherty, G. M., Mandel, S. J., Nikiforov, Y. E., Pacini, F., Randolph, G. W., Sawka, A. M., Schlumberger, M., et al. (2016) · Thyroid® · doi:10.1089/thy.2015.0020 · Cited by 16,535
Self-citationCooper, D. S., Doherty, G. M., Haugen, B. R., Kloos, R. T., Lee, S. L., Mandel, S. J., Mazzaferri, E. L., McIver, B., Pacini, F., Schlumberger, M., et al. (2009) · Thyroid · doi:10.1089/thy.2009.0110 · Cited by 6,707
Self-citationCooper, D. S., Doherty, G. M., Haugen, B. R., Kloos, R. T., Lee, S. L., Mandel, S. J., Mazzaferri, E. L., McIver, B., Sherman, S. I., & Tuttle, R. M. (2006) · Thyroid · doi:10.1089/thy.2006.16.109 · Cited by 2,016
Pacini, F., Schlumberger, M., Dralle, H., Elisei, R., Smit, J. W. A., Wiersinga, W., & _, _. (2006) · European Journal of Endocrinology · doi:10.1530/eje.1.02158 · Cited by 1,976
Self-citationDurante, C., Haddy, N., Baudin, E., Leboulleux, S., Hartl, D., Travagli, J. P., Caillou, B., Ricard, M., Lumbroso, J. D., De Vathaire, F., et al. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2838 · Cited by 1,675
Metadata
- Authors
- Pacini, F.
- Venue
- Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2001-09-01
- Volume
- 86
- Issue
- 9
- Pages
- 4092-4097
- ISSN
- 0021-972X (ISSN-L)
- OpenAlex
- W2091271755
- Cited by
- 268
- References
- 17
- FWCI
- 8.09
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.